Gracell
THERAPEUTIC AREA
Cell therapy
YEAR INVESTED
2023
STAGE
IPO'd in 2021; acquired by AstraZeneca in 2024
WEBSITE
Gracell Biotechnologies is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapy. The company is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates to overcome major industry challenges that persist with conventional CAR-T therapies.
